within Pharmacolibrary.Drugs.ATC.L;

model L04AG16
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 4.9999999999999996e-06,
    adminDuration  = 600,
    adminMass      = 420 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0067,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0033,
    k12             = 0.41,
    k21             = 0.41
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AG16</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Rozanolixizumab is a humanized monoclonal antibody targeting the neonatal Fc receptor (FcRn), used for the treatment of generalized myasthenia gravis (gMG) in adults. It functions by reducing IgG levels and is approved for clinical use in several regions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were derived from clinical studies in adult patients with generalized myasthenia gravis following subcutaneous administration.</p><h4>References</h4><ol><li><p>Smith, B, et al., &amp; Brennan, FR (2018). Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. <i>mAbs</i> 10(7) 1111–1130. DOI:<a href=&quot;https://doi.org/10.1080/19420862.2018.1505464&quot;>10.1080/19420862.2018.1505464</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30130439/&quot;>https://pubmed.ncbi.nlm.nih.gov/30130439</a></p></li><li><p>Matic, A, &amp; Bril, V (2025). Rozanolixizumab for Myasthenia Gravis: a breakthrough treatment and future prospects. <i>Immunotherapy</i> 17(5) 309–316. DOI:<a href=&quot;https://doi.org/10.1080/1750743X.2025.2491295&quot;>10.1080/1750743X.2025.2491295</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/40277145/&quot;>https://pubmed.ncbi.nlm.nih.gov/40277145</a></p></li><li><p>Kiessling, P, et al., &amp; Jolles, S (2017). The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study. <i>Science translational medicine</i> 9(414) –. DOI:<a href=&quot;https://doi.org/10.1126/scitranslmed.aan1208&quot;>10.1126/scitranslmed.aan1208</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29093180/&quot;>https://pubmed.ncbi.nlm.nih.gov/29093180</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AG16;
